Chemoimmunotherapy for Aggressive Variant Prostate Cancers (AVPC)
Abstract
Men with androgen indifferent prostate cancers have a dismal prognosis and limited treatment options. To provide a framework for their study and therapy development, we defined the aggressive variant prostate cancers (AVPC) and in previous studies obtained evidence that men with AVPC benefit from the addition of carboplatin to cabazitaxel chemotherapy, and likely from PARP inhibitor maintenance following chemotherapy induction. Building on this work and based on the evidence of immune-modulation by chemotherapy and PARP inhibitors in preclinical studies, as well as the clinical benefit observed with the addition of immune-checkpoint therapy to chemotherapy in patients with aggressive malignancies that share similarities with the AVPC, we hypothesized that PD-1 inhibition will enhance the anti-tumor response of platinum-based chemotherapy induction and PARP inhibitor maintenance in men with AVPC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1191289
Entities
People
- Ana Aparicio
Organizations
- The University of Texas MD Anderson Cancer Center